The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5108	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5109	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5110	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5111	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5112	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5113	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5114	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5115	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5116	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5117	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5118	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5119	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5120	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result90% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5121	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5122	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5123	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineATCC	Origin of cell lineHuman melanoma cell line	Cell lineSK-MEL-2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5124	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for B16-OVA (1.0E+5 cells)	In-vivo virus concentration3.0E+6 on day 0 and 1.0E+6 on day 2	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic mm compared to control 500 cubic mm after 12 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5125	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for B16-OVA (1.0E+5 cells)	In-vivo virus concentration3.0E+6 on day 0 and 1.0E+6 on day 2	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volumecompared to control 500 cubic mm after 12 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5413	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5414	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5415	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5416	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS-40	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5417	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS-40	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5418	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine lymphosarcoma cell line	Cell lineRLS-40	Concentration of cell line80% confluence	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5419	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine melanoma	Cell lineB16	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result57% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5420	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine melanoma	Cell lineB16	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result42% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5421	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineMurine melanoma	Cell lineB16	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result22% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5422	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result64% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5423	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5424	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-3-1	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result17% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5425	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5426	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5427	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineRussian academy of science	Origin of cell lineHuman cervical carcinoma	Cell lineKB-8-5	Concentration of cell line9.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result35% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5428	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57Bl6 mice subcutaneous injected for 1.0E+5 B16 cells	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 0.3 cubic cm compared to control 1.2 cubic cm after 20 days	Mode of deliveryIntratumoral	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5429	Virus nameVaccinia virus	Virus strainLIVP-GFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion mutant for tk gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCBA mice sintramuscularly injected for 5.0E+7 RLS-40 cells	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 0.2 cubic cm compared to control 0.8 cubic cm after 15 days	Mode of deliveryIntratumoral	Pathway inducedReduction production of IL-6 indicating tumor inhibition	Immunogenic effectNA	Clinical trialNA	PMID27538520
IDOV_5457	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5458	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5459	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice injected with tumor	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultMice failed to develop cancer	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS41098983
IDOV_5682	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 261.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5683	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 248.4mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5684	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 216.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5685	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 208.8mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5686	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 157.2mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5687	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 280.3mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5688	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 301.9mm compared to control 240.8 mm after 33 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5689	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 273.5mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5690	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 243.8mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5691	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 286mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5692	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 267.1mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5693	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 155.6mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5694	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 310.9mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5695	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 416.9mm compared to control 263.6 mm after 36 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5696	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 536.1mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5697	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 5550.4mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5698	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 463.4mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5699	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 543.3mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5700	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 320.1mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5701	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 679mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5702	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 660mm compared to control 579.1 mm after 43 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5703	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 701.4mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5704	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 761.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5705	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 706.6mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5706	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 721.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5707	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 476.3mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5708	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 864.1mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5709	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 828.6mm compared to control 636.4 mm after 50 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5710	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 978.4mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5711	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 852mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5712	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 985.5mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5713	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 936.1mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5714	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 695mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5715	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1179.9mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5716	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 897.4mm compared to control 671.6 mm after 57 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5717	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1485mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5718	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1053mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5719	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 852mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5720	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 606mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5721	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 751mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5722	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 166.7mm compared to control 2715 mm after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5723	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 92 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5724	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 1536.9mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5725	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 962.2mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5726	Virus nameVaccinia virus	Virus strainGLV-1h70	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, LacZ gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 579.2mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5727	Virus nameVaccinia virus	Virus strainGLV-1h71	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 546.9mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5728	Virus nameVaccinia virus	Virus strainGLV-1h72	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA and LacZ at F14.5L gene locus and TK and HA gene locus respectively using P11k vector	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 720.1mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5729	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 117.8mm compared to control 2918.3 mm after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5730	Virus nameVaccinia virus	Virus strainGLV-1h74	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, noncoding DNA at TK locus and HA gene locus in gusA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 97 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5731	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 412.9mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5732	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 350.2mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5733	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 341.1mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5734	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 353.4mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5735	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 392.25mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5736	Virus nameVaccinia virus	Virus strainGLV-1h84	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of F14.5L gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 305.6mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5737	Virus nameVaccinia virus	Virus strainGLV-1h85	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA into F14.5L gene, TK gene at place of LacZ and gusA gene at place of HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 350.65mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5738	Virus nameVaccinia virus	Virus strainGLV-1h86	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP into F14.5L gene, noncoding DNA at place of LacZ and HA gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 419.55mm after 39 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5739	Virus nameVaccinia virus	Virus strainGLV-1h22	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 750.4mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5740	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP, non coding DNA at F14.5L gene locus and TK and HA gene locus using psel vectorrespectively	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 722.3mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5741	Virus nameVaccinia virus	Virus strainGLV-1h73	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of noncoding DNA at F14.5 locus, LacZ gene at TK gene, noncoding DNA into HA locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 819.8mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5742	Virus nameVaccinia virus	Virus strainGLV-1h82	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1081.2mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968
IDOV_5743	Virus nameVaccinia virus	Virus strainGLV-1h83	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of Ruc-GFP gene at place of HA gene under Psel promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd athymic nude mice xenograft for GI-101A human breast carcinoma cells (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume becomes 1222.25mm after 47 days	Mode of deliveryIntravenously	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMIDUS8052968